Junior Biotech Roche (OTCBB: RHHBY) to Start Human Trials in Quest for New Breast Cancer Treatments

Atlanata, GA 5/10/12 (StreetBeat) – The battle against breast cancer looks to be getting a few more weapons in its arsenal in the future. Swiss drug giant Roche took a shot in the arm in November of 2011 when the Food and Drug Administration revoked their Genentech unit’s Avastin as an indication for breast cancer, but Roche (OTCBB: RHHBY) is providing some promising research with their new pertuzumab drug in recent months. The experimental antibody is being used as an addition to Roche’s blockbuster breast cancer drug, Herceptin, and chemotherapy. The latest data shows that the new concoction can add six months to the lives of HER2-positive breast cancer patients. Herceptin, also known as tratuzumab, had 2010 global sales of $6.8 billion.

On the same front, other drug makers are providing optimistic results across the full range of research. Novartis's (NYSE:NVS) is developing Afinitor (everolimus) - which is already approved for other cancers - showed that treatment with it delays disease progression by four months among metastatic patients. Earlier on in development, Sunshine Biopharma(OTCBB:SBFM) is wrapping-up laboratories studies on Adva-27, a small molecule that targets and inhibits Top2, the second enzyme (HER-2 is the other) associated with aggressive forms of breast cancer. Also taking a step in the right direction helping to re-shape the treatments for breast cancer patients is Seattle, Washington-based TapImmune Inc. (OTCBB:TPIV).

A vaccine technology company, TapImmune received allowance from the FDA last year and recently got Institutional Review Board approval for a Phase I clinical trial to be hosted at the Mayo Clinic in Rochester, Minnesota. Today, TapImmune told investors that the company-sponsored trial is set to begin to test its novel set of HER2/neu Class II antigens in breast cancer patients who finished standard Herceptin-based therapy and are at a high risk of disease recurrence.

As a result of what the company called an “overwhelming response” from patients expressing interest to be in the trial, TapImmune expects the trial to be fully subscribed. The primary endpoints of the study will be safety and immunogenicity - the ability of a particular substance, such as an antigen or epitope, to provoke an immune response in the body of a human or animal. Representing a significant milestone, this is the first clinical trial to be run to test TapImmune’s HER-2/neu vaccine program.

There are four companies with four different root targets for the treatment of breast cancer with each striving to generate revenue while providing a solution to a disease that took the life of approximately 40,000 women in 2011, with about 300,000 new cases diagnosed. Proper due diligence on each is, as always, encouraged.

Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly

TapImmune, Inc. (OTCBB: TPIV) Trading +22%

Tallahassee, FL 10/27/11 (PennyPayDay) --Shares of micro-cap biotech TapImmune, Inc. (OTC.BB: TPIV) have seen a steady increase in volume and trading activity in recent weeks. At a volume of 1.3M (much greater than the 109,375 average volume during the regular season), shares are currently trading at $0.26, up 22%,

With the World Health Organization's recent vocal announcements of growing threats that multidrug-resistant and extensively drug-resistant forms of tuberculosis are spreading at an alarming rates in Europe, investors have once again begun to pay more attention to TPIV, which holds promise as both an anti-cancer and bio-defense play. TapImmune continues working with the likes of the Mayo Clinic and Aeras Foundation on vaccine candidates in both Cancer and Infectious Diseases.

The company has been quietly building solid relationships within industry because of the relevance of the TAP technology and BioMedReports continues to expect positive developments from the firm, particularly with CEO Dr. Glynn Wilson on the verge of presenting data from the clinic on TAP levels and its affect on disease progression. There is growing evidence now from around the world showing that TAP is indeed a key component in the antigen presentation process and where it is lacking or down regulated, disease progresses and prognosis is worse.

The Seattle based company's TAP-based prophylactic vaccine -- which initial tests indicate may increase the efficacy of targeted prophylactic vaccines by up to 1000 times -- may significantly improve the efficacy of many current prophylactic vaccines and enhance the creation of new ones in the fight against many pandemic infectious diseases.

A next generation smallpox vaccine is currently in preclinical development and the company has been busy working with Gregory Poland, the head of the Mayo Clinic's Vaccine Research Group, who is working to unite the fields of genomics and vaccinology. That work has come about, in part, because Poland and others have never been fully pleased with the existing vaccine paradigm.

PennyPayDay Disclaimer

Distributed by Viestly

TapImmune (TPIV) Technical Stock Chart Video

Looking to come off the bottom, the TPIV chart had a volume surge on Friday and closed green for the day. The PPS has pushed back up to grab support at 15 and 16 cents with technical traders looking for volume to continue to push the chart back towards resistance at 21 cents.

Distributed by Viestly

TapImmune (TPIV) Technical Stock Chart Video

The TapImmune chart has been channeling sideways now for several weeks. While the indicators are somewhat neutral, at this point they are leaning towards the bullish side of things which will have traders watching for a potential breakout of the topside of the channel.

Distributed by IntelBuilder Social Media Platform

TapImmune (OTC:TPIV) Raises $1.16M from PIPE

TapImmune (OTC:TPIV) announced today the closing of a $1.16M funding. As I write, shares of TapImmune are up 3 percent at $0.17 per share on light volume of 9,000 shares. The company has a market cap of $6.8 million.

On February 24, 2011, TapImmune entered into a securities purchase agreement with accredited investors in the amount of $1,159,413. A portion of the net proceeds of the financing was used to prepay some outstanding notes and to purchase and retire 11,200,000 warrants to purchase shares of common stock. The remainder will be used for general corporate matters and for other expenses related to the company’s clinical programs and partnerships. Full details of the transaction can found in the company’s 8K filed with the SEC today.

“We are pleased to be able to retire such a large portion of the outstanding registered warrants issued last May. We believe this will remove a significant overhang from our capital structure and enable us to consummate longer term financing opportunities as we start our clinical programs," said Denis Corin, TapImmune's CFO.

TapImmune's approach is designed to increase the efficacy of vaccines by enhancing antigen presentation through the use of the Transporter of Antigen Processing ('TAP'). Replacement of this transporter provides a significant immune response with the potential to treat a variety of cancers which lack normal amounts of TAP.

For more information, please visit TapImmune’s website www.tapimmune.com.

Distributed by IntelBuilder Social Media Platform